Dr. Beauregard is an assistant professor in the Department of Radiology and Nuclear Medicine at Laval University, a clinician scientist in the Oncology axis of the CHU Research Centre of Quebec – Laval University, and a specialist in nuclear medicine in the Department of Medical Imaging of the CHU of Quebec. Dr. Jean-Mathieu Beauregard completed his residency in nuclear medicine and his master’s degree in radiobiology at the Université de Sherbrooke. He completed additional training at the Peter MacCallum Cancer Centre in Melbourne, Australia from 2007 to 2010, during which he developed a strong interest in molecular imaging and radionuclide therapy for neuroendocrine tumors. Since his return to the CHU of Quebec, he has set up a new radiopeptide therapy program for neuroendocrine tumors. His research program is multidisciplinary and integrates translational research projects in medical and clinical physics.

Dr. Beauregard’s main clinical research project is the radiopeptide therapy (or PRRT for peptide receptor radionuclide therapy) of patients with neuroendocrine tumors (NETs), where a radioligand (ex. 177Lu-octreotate), binding to the somatostatin receptor expressed by NETs, is administered in several cycles to deliver radiotherapy said internal. We have developed an innovative approach, the personalization of the administered activity, to achieve safe target doses of radiation absorbed by healthy tissue, in order to maximize the irradiation of tumors, without increasing the treatment’s toxicity. Our preliminary results show that we are substantially increasing the radiation dose to tumors compared to the standard regimen where all patients receive the same activity at each cycle.

At the same time, we are working to improve and simplify dosimetry based on SPECT / CT quantitative imaging. To this end, we are fine-tuning the calibration of the SPECT / CT cameras and optimizing the sequence of serial imaging of patient performed after each PRRT treatment cycle in order to achieve the highest precision possible with a minimum of imaging sessions. These serial studies allow us to evaluate the biodistribution of the radiopharmaceutical and its kinetics in different tissues and tumors to derive absorbed radiation doses.

In collaboration with Dr. Girish M. Shah, we are also conducting in vitro and in vivo translational research projects, evaluating novel approaches to PRRT potentiation. One of these is the coadministration of radiosensitizing molecules, such as poly (ADP-ribose) and polymerase (PARP) inhibitors. These inhibit the repair of damages caused to the tumors’ DNA by the PRRT, and thus amplify the therapeutic effects. Another strategy we are studying is to pre-treat NET cells with molecules that can increase their somatostatin receptor expression, thereby promoting increased PRRT radiopharmaceutical accumulation within these cells.

Finally, Dr. Beauregard is also a co-investigator and collaborator on several other clinical research projects using, among other things, positron emission tomography (PET / CT) molecular imaging of prostate cancer and neurodegenerative disorders. Dr. Beauregard supervises graduate students and clinical fellows as part of a complementary training program in nuclear oncology.

45 entries « 1 of 5 »

Brosch-Lenz J, Yousefirizi F, Zukotynski K, Beauregard JM, Gaudet V, Saboury B, Rahmim A, Uribe C

Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical Therapies.

Journal Article

PET Clin, 16 (4), 2021.

Abstract | Links:

Huot Daneault A, Desaulniers M, Beauregard JM, Beaulieu A, Arsenault F, April G, Turcotte É, Buteau FA

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With Lu-DOTATATE: A Case Report.

Journal Article

Front Endocrinol (Lausanne), 12 , 2021.

Abstract | Links:

Zhang H, Koumna S, Pouliot F, Beauregard JM, Kolinsky M

PSMA Theranostics: Current Landscape and Future Outlook.

Journal Article

Cancers (Basel), 13 (16), 2021.

Abstract | Links:

Shah RG, Merlin MA, Adant S, Zine-Eddine F, Beauregard JM, Shah GM

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells.

Journal Article

Cancers (Basel), 13 (2), 2021.

Abstract | Links:

Clarke MTM, St-Onge F, Beauregard JM, Bocchetta M, Todd E, Cash DM, Rohrer JD, Laforce Jr

Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers.

Journal Article

Alzheimers Res Ther, 13 (1), 2021.

Abstract | Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallee E, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Journal Article

Can Urol Assoc J, 2021.

Abstract | Links:

Hou X, Brosch J, Uribe C, Desy A, Boning G, Beauregard JM, Celler A, Rahmim A

Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.

Journal Article

J Nucl Med, 62 (7), 2021.

Abstract | Links:

Desy A, Bouvet GF, Frezza A, Despres P, Beauregard JM

Impact of dead time on quantitative Lu-SPECT (QSPECT) and kidney dosimetry during PRRT.

Journal Article

EJNMMI Phys, 7 (1), 2020.

Abstract | Links:

Frezza A, Desport C, Uribe C, Zhao W, Celler A, Despres P, Beauregard JM

Comprehensive SPECT/CT system characterization and calibration for Lu quantitative SPECT (QSPECT) with dead-time correction.

Journal Article

EJNMMI Phys, 7 (1), 2020.

Abstract | Links:

Adant S, Shah GM, Beauregard JM

Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.

Journal Article

Eur J Nucl Med Mol Imaging, 47 (4), 2020.

Abstract | Links:

45 entries « 1 of 5 »
Signaler des ajouts ou des modifications

Active projects

  • Chemotherapy-induced upregulation of somatostatin receptors for enhancing therapeutic efficacy of, and eligibility to PRRT of neuroendocrine tumors, from 2020-07-01 to 2022-12-31
  • National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2022-06-30

Recently finished projects

  • Bourses d'aide au démarrage d'études cliniques en oncologie effectuées à l'initiative des chercheurs , from 2019-06-06 to 2020-03-31
  • Implantation de la TEP/TDM au Ga68-octreotate dans le cadre de la mise en image des récepteurs à la somatostatine , from 2018-04-01 to 2020-03-31
  • Therapie radiopeptidique personnalisee des patients atteints de tumeurs neuroendocrines, from 2018-07-01 to 2020-06-30
  • Upregulating expression of SSTR to enhance PRRT of neuroendocrine tumors, from 2017-02-01 to 2020-01-31
Data provided by the Université Laval research projects registery